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ABSTRACT 
Dementia in advanced Parkinson’s Disease (PD) is a fatal milestone resulting in reduced life expectancy and nursing home 
placement. Cognitive impairment and cardiovascular dysautonomia are common and debilitating non-motor symptoms that 
frequently coexist in PD since the early stages and progress in subsequent years. 
In particular, blood pressure (BP) abnormalities, including orthostatic hypotension (OH), supine hypertension (SH) and the loss 
of nocturnal BP fall (non-dipping) in PD have been associated with cognitive deterioration. They usually have multifactorial 
aetiology, including neuronal (central and peripheral) mechanisms and concomitant intake of medications. BP abnormalities 
can influence cognition in many ways, including repeated cerebral hypoperfusion leading to cerebral ischaemic lesions, higher 
burden of white matter hyperintensities, and possible impact on neurodegenerative process in PD. They are often asymptomatic 
and remain unrecognised, hence 24-hour ambulatory BP monitoring is recommended in patients with clinical symptoms of 
dysautonomia. Management is challenging and should address the multifactorial nature of BP disturbances. The aim of this 
review was to present the state of current knowledge regarding the possible relationship between cardiovascular dysautonomia 
and cognition in PD, its diagnosis and treatment. 
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Introduction
Parkinson’s Disease (PD) is, after Alzheimer’s Disease 
(AD), the most frequent neurodegenerative disorder. Brady-
kinesia, tremor, rigidity and postural instability are the most 
prominent motor features. PD pathophysiology includes the 
impairment of not only dopaminergic but also cholinergic, 
serotoninergic and noradrenergic systems. Therefore, cog-
nitive decline, sleep and mood disorders, gastrointestinal, 
genitourinary or cardiovascular disturbances are common 
since early stages and deteriorate with disease progression [1]. 
Among cardiovascular abnormalities there have been noted 
orthostatic hypotension (OH), supine hypertension (SH) and 
the absence of a decrease of blood pressure (BP) during the 
night [2]. The aetiology of BP abnormalities in PD patients 
is multifactorial. It is neurogenic, regarding the pathophys-
iology of PD and both peripheral and central denervation, 
but also influenced by treatment, as almost all dopaminergic 
medications (levodopa, dopamine agonists) can decrease BP 
[3]. Dysautonomia and Parkinson’s Disease-related dementia 
(PDD) are the most disabling non-motor symptoms resulting 
in short life expectancy and nursing home placement [4]. 
The pathogenesis of cognitive impairment in PD remains 
unclear [5]. Combination of Lewy- and Alzheimer-pathology 
have presumably an additive effect on cognition impairment 
[6]. Apolipoprotein E polymorphism (ε4 allele) was also 
considered as a risk factor for PDD, although results are 
inconsistent, with negative impacts [7, 8], not confirmed in 
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other studies [9, 10]. Also genetic forms of PD (mutations in: 
α synuclein gene – SNCA, leucine-riche repeat serine/threo-
nine protein kinase gene - LRRK2) or specific genes variants 
(glucocerebrosidase – GBA, microtubule-associated protein 
tau – MAPT, and catechol-o-methyl transferase – COMT) can 
influence cognition in PD [11, 12]. 
The relationship between cardiovascular risk factors and 
cognition in PD studies remains inconclusive [13–17]. 
White matter hyperintensities (WMH) — T2 hyperintense 
lesions seen on magnetic resonance imaging (MRI) scans, may 
result from cerebrovascular disease. Several studies have indi-
cated a negative impact of WMH on cognition in PD [2, 14, 18, 
19]. Increasing WMH volume leads to deteriorations in execu-
tive function, memory and language [20]. Correlation between 
WMH and progression from mild cognitive impairment (MCI) 
to PDD has been also described [21]. Higher scores of WMH 
rating scales have been observed in a group of PD patients with 
MCI and PDD than in a group with normal cognition [14, 20, 
22], but these results were not confirmed in other studies [23, 24]. 
Autonomic dysfunction, especially BP fluctuations, are 
an early manifestation of the disease, more pronounced in 
advanced stages and may result (as part of the neurodegen-
erative process) in cognitive decline. Its aetiology might be 
multifactorial and likewise in AD, vascular risk factor po-
tentially might be an important co-factor or even trigger the 
neurodegeneration. 
The aim of this review was to present the current state of 
knowledge regarding the relationship between cardiovascular 
dysautonomia (with the particular role of OH, SH and non-
dipping effect) and cognition in PD (Fig. 1).
Pathophysiology of dysautonomia 
in Parkinson’s Disease
Structural — central and peripheral nervous 
system involvement
Autonomic dysfunction in PD has a complex aetiology, 
involving both central and peripheral mechanisms (Tab. 1) 
[25]. Neuronal loss and Lewy bodies (with neuronal cyto-
plasmatic inclusions of α-synuclein) are observed not only in 
the zona compacta of the substantia nigra, but also in regions 
responsible for the control of autonomic functions such as 
the hypothalamus, nucleus vagus dorsalis, intermediolateral 
column of spinal cord and sympathetic ganglia, myenertic and 
submucosal plexus of intestines [26]. 
In healthy subjects, baroreceptors response caused 
by standing results in noradrenaline release from sympa-
thetic post-ganglionic nerves causing vasoconstriction. 
This mechanism maintains BP in a standing position [27]. 
Post-ganglionic sympathetic neuron degeneration is the main 
cause of cardiovascular dysautonomia in PD [27, 28]. Sym-
pathetic denervation of the heart in PD has been shown in 
123I-meta-iodobenzylguanidine (MIBG, radioactive molecu-
lar analogue of noradrenaline) scintigraphy (low myocardial 
uptake) and in neuropathological studies (fibres loss) [29, 
30]. The neuropathological hallmark of PD - Lewy bodies 
(LB) were found in cardiac plexus of patients with PD [31]. 
The function of extracardiac peripheral sympathetic nervous 
system is also impaired, affecting sympathetic innervation 
of blood vessels interfering with noradrenaline release and 
vasoconstriction in a standing position [28]. Mean resting 
Cardiovascular dysautonomia 
in Parkinson's disease 
Orthostatic hypotension Abnormal nocturnal blood 
pressure 
Supine hypertension
• WMH development 
• cerebral hypoperfusion 
• widespread neurodegeneration 
• peripheral noradrenergic dysfunction 
• other mechanisms (?) 
Possible impact on cognitive 
deterioration in PD
Figure 1. Cardiovascular dysautonomia in Parkinson’s Disease: possible mechanisms linking it with cognitive impairment
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Table 1. Central and peripheral autonomic structures affected in Parkinson’s Disease (modified according to [25])
Autonomic structures affected in PD
Central Peripheral 
Hypothalamus + Enteric nervous system + +
Periaqueductal grey + Postganglionic sympathetic neurons + +
Ventrolateral medulla + Cholinergic sudomotor +
Medullary raphe + Noradrenergic cardiac + + +
Dorsal motor nucleus of vagus + + + Noradrenergic vasomotor +
Nucleus ambigus + Adrenal gland +
Pontine micturion centre – Postganglionic parasympathetic neurons + +
Sacral perganglionic neurons + Submandibular gland + +
Gonadal tissue +
Onuf nucleus + Pelvic ganglia +
PD — Parkinson’s Disease
noradrenaline plasma levels in PD-OH patients is lower com-
pared to patients without OH [32, 33]. Furthermore, during 
tilt test this level decreases in PD-OH group [33], whereas 
normally it should double after five minutes of standing [34]. 
Additionally, in this group of patients systolic BP increased 
after administration of low doses of adrenoreceptor agonists. 
This implies vascular adrenoreceptor supersensitivity result-
ing from noradrenaline deficiency [35]. It also proves extra-
cardiac sympathetic denervation. Patients with neurogenic 
OH in phase II of Valsalva manoeuvre present a progressive 
BP decrease and lack of BP overshoot during phase IV, which 
suggests baroreflex sympathetic failure [28]. This may also 
lead to SH. Neurogenic OH may result in heart rate blunted 
response while changing from a supine/sitting position to 
standing [36]. Orthostatic hypotension with increase in 
heart rate ≤ 15 bpm [36] or baroreflex gain < 0.5 bpm/mmHg 
(change in heart rate/ falling systolic blood pressure (SBP)) 
[37] can help to distinguish neurogenic from non-neurogenic 
OH. Furthermore, cardiac responses to orthostatic stress
deteriorate in PD patients who begin to fall [38]. Moreover,
Tipre et al. [39] observed among PD-OH group a decreased
renal sympathetic innervation, presumably leading to natri-
uresis and diuresis, thus increasing susceptibility to blood
volume depletion.
Levodopa intake (the main medication used in PD treat-
ment), even when combined with carbidopa or benserazide, 
increases plasma levels of dopamine and its metabolites. This 
results in vasodilatation (via dopamine receptors on smooth 
muscle cells) and increased natriuresis and diuresis, which 
leads to a reduction of blood volume and extracellular fluid 
[28]. In PD patients, both baroreflex and cardiovascular 
sympathetic innervations are impaired, and together these 
mechanisms may result in BP decrease [27, 28]. However, 
Noack et al. [40] suggested that hypotension response to lev-
odopa may be caused by negative cardiac inotropism rather 
than vasodilatation. 
The relationship between central autonomic structures 
involvement and dysautonomia manifestations in PD is poorly 
understood [25]. Affected structures are presented in Table 1. 
The suprachiasmatic nucleus (SCN) of the hypothalamus, as 
the central biological clock, regulates circadian rhythm of BP 
and heart rate [41]. The SCN stimulates autonomic nervous 
system not only through GABA-ergic neurons, but also by 
regulation of melatonin release [41]. De Pablo-Fernandez et 
al. in a neuropathological case control study found α-synuclein 
depositions in the SCN of PD patients [26], and another group 
observed blunted circadian rhythm of melatonin serum levels 
in PD compared to controls [42]. Nucleus coeruleus, a main 
source of noradrenaline in the brain, is affected in the early 
stage of the disease [43] and noradrenaline transporter density 
is decreased [44]. The number of catecholaminergic neurons 
of nucleus of the solitary tract is reduced, which could be 
connected with the baroreflex impairment [45]. 
In PD-OH patients, the increased density of Lewy Bod-
ies in the insular cortex has been observed [46] along with 
a reduced functional connectivity between hypothalamus, 
thalamus and striatum [47]. 
Orthostatic hypotension
Orthostatic hypotension (OH) is a common nonmotor PD 
manifestation (30% of patients) [48] and increases with age, dis-
ease duration, its severity and LD equivalent dose (LEDD) [49]. 
It is defined as a reduction in SBP ≥ 20 mmHg or ≥ 10 mmHg 
in diastolic blood pressure (DBP) after 3 minutes of standing 
from a supine position. In some patients, testing should be pro-
longed, as they may suffer from a delayed OH [50]. Standards 
for such testing have not been provided yet. Delayed OH can 
evolve to classic OH after 10 years in up to 50% of cases [50]. 
Although age is one OH risk factor, it can also be observed in 
early stages of the disease and is one of the diagnostic markers 
of prodromal PD in the Movement Disorder Society’s research 
criteria [51, 52], predicting motor decline in this group [53]. 
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Blood pressure drop during an orthostatic test depends on 
the duration of rest before supine BP measurement, the way of 
obtaining upright position (active stand or passive tilt), and 
the duration of standing [54]. Orthostatic hypotension in PD 
occurs more frequently after tilting than on standing and is 
often delayed [54]. Symptomatic OH presents as light-head-
edness, dizziness, presyncope, syncope, visual disturbances, 
fatigue, and generalised weakness [36]. Both symptomatic and 
asymptomatic OH are associated with an increased prevalence 
of falls, hospital admissions and lower quality of life [55]. 
MCI may be present at the early stage of PD in 25% of 
patients and may develop into dementia in up to 78% after 
12 years of follow up [56]. 
Several pathological mechanisms are considered to be 
responsible for the relationship between OH and cognition, 
such as cerebral hypoperfusion as a result of recurrent episodic 
hypotension, widespread neurodegeneration, or central and 
peripheral noradrenergic dysfunction [27, 57, 58]. 
In several cross-sectional studies, a positive correlation 
between OH and cognitive deterioration has been observed 
(Tab. 2). Attentional/executive and visuospatial functions were 
more impaired among patients with OH [58]. Age, male sex, 
baseline REM-sleep Behaviour Disorder (RBD), OH and MCI 
have been identified as predictors of PDD [59, 60]. In studies 
that included only a Mini Mental State Examination (MMSE) 
in the neuropsychological assessment, OH did not influence 
cognition [61–63]. MMSE is a screening tool dedicated to AD 
that may be not sensitive enough, and is not indicated as the 
only tool to diagnose cognitive decline in PD.
Cicero et al. [4] examined the correlation between car-
diovascular autonomic function and MCI among 185 PD 
patients from two Movement Disorders centres. Orthostatic 
hypotension was recorded in 52 of them, significantly more 
frequently in patients with long disease duration, and was 
associated with amnestic MCI.
The relationship between OH and posture-related cog-
nitive impairment in PD has been investigated, comparing 
cognition among PD patients with and without OH to controls. 
Groups were matched for age, sex, premorbid verbal IQ and 
PD groups also for disease stage/duration and LEDD. In supine 
position, both PD groups demonstrated fronto-striatal and 
visuospatial cognitive deficits, but a transient exacerbation of 
cognition in an upright-tilted position was observed only in 
PD-OH group [65]. Sforza et al. replicated these findings in 
a small cohort of 28 PD patients [66]. Additionally, asystolic 
drop was greater and attention more deteriorated among PDD 
than PD patients while standing [67]. 
Differences in cognitive impairment between sympto-
matic and asymptomatic PD-OH patients were compared in 
the Longardner et al. study. The first part was performed as 
a cross-sectional, retrospective study and included 226 PD 
patients of whom 62 had longitudinal follow-up (second part). 
Lower Montreal Cognitive Assessment (MoCA) scores and 
worse decline during follow-up period were observed among 
PD-OH group. Presence of OH symptoms did not influence 
cognitive deterioration [68]. 
It is still unclear whether the relationship between OH 
and cognitive dysfunction is causative or associative, because 
the results of some studies were not adjusted for important 
variables e.g. comorbidities, medications, or age [57]. 
Supine hypertension 
In approximately 50% of PD-OH patients, orthostatic 
hypotension often coexists with supine hypertension (SH) [69, 
70]. Patients with SH often have an abnormal nocturnal BP 
profile as well [2]. SH is defined as a SBP ≥ 140 mmHg or a DBP 
≥ 90 mmHg after at least 5 min of rest in supine position [71]. 
This is often overlooked, because BP is usually measured in 
a seated position and it remains asymptomatic. The underlying 
mechanisms may result from baroreflex failure or vascular 
hypersensitivity, or both mechanisms combined [71]. SH is 
probably associated with milder peripheral sympathetic den-
ervation than OH alone [72].  Older age, akinetic-rigid motor 
subtype (predisposing to cognitive decline), and pre-existing 
hypertension are independent risk factors [72]. SH alone can 
cause cognitive impairment and white matter hyperintensities 
(WMH), also in early PD [2]. The impairment is more severe 
when SH is combined with OH [2]. However, a few studies 
did not confirm this observation [68, 69, 73]. 
Palma et al. [74], in a prospective study of patients with 
α-synucleinopathies (35 with multiple system atrophy, 14 with 
PD, and eight with pure autonomic failure) and coexisting OH, 
observed that SH is associated with an increased risk of left 
ventricular hypertrophy, higher blood urea nitrogen levels, 
glomerular filtration rate decrease and WMH volume, and, in 
longitudinal observation, with cardiovascular adverse events 
and premature death. Both chronic SH and OH are associated 
with the development of WMH [75]. 
Abnormal nocturnal blood pressure 
Physiologically, BP follows a circadian rhythm charac-
terised by a decrease of >10% BP at night (dipping) [76]. An 
abnormal nocturnal BP profile is another frequent manifesta-
tion of autonomic dysfunction in PD. Most PD patients present 
as either non-dippers or reverse dippers (also called risers) 
i.e. with loss of nocturnal BP fall or even an increase of BP
values during the night, respectively [76, 77] (Fig. 2). These
disturbances of circadian BP pattern have been associated
with coronary heart disease, stroke and increased mortality
[77]. Furthermore, they have been linked with target organ
damage, impairment of cognition in the elderly, and increased 
burden of WMH [77, 78].
The literature on the disturbances of the circadian BP 
rhythm in PD is scarce and only a few studies have explored 
this topic. Tanaka et al. [77] assessed 137 PD patients with 
24-hour ambulatory BP monitoring, MMSE, the Hasegawa
dementia scale-revised (HDS-R), Hoehn and Yahr scale (H&Y) 
and MRI. Twenty-seven patients met the diagnostic criteria
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Table 2. Studies on association between orthostatic hypotension and cognitive decline (modified according to [58], with supplement of later studies)
Study Design Subjects Cognitive outcome 
Allcock et al. 
(2004) [62]
Cross-sectional PD-OH, n = 42, mean age 72.6
PD without OH, n = 45, mean age 68.2
No difference in MMSE score between two groups
Allcock et al. 
(2006) [63]
Cross-sectional PD-OH, n = 80, mean age 72.1, median UPDRS 19, 
median PD duration 3 years
PD without OH, N = 79, mean age 69.1, median 
UPDRS 17, median PD duration 5 years
No difference in MMSE score between two groups
Allcock et al. 
(2006) [96]
Cross-sectional PD-OH, n = 87, mean age 72.4, median UPDRS 18.5, 
median PD duration 3.5 years
PD without OH, n = 88, mean age 69.2, median 
UPDRS 17, median PD duration 5 years
PD-OH group performed worse on digit vigilance and 
picture recognition tasks.
No difference in MMSE score between two groups
Peralta et al. 
(2007) [67]
Cross-sectional PD, n = 10, mean age 74.1, mean disease duration 6.4 
years, mean H&Y 2.1
PDD, n = 8, mean age 77.3, mean disease duration 
7.8, mean H&Y 2.9
OH in 5 PDD, 2 PD. Decrease in attention scores in 
PDD in tilt position. Significant correlation between 
orthostatic changes and attention scores in PDD and 
no influence on word fluency tasks observed. Results 
not adjusted for dopaminergic medication
Idiaquez et al. 
(2007) [61]
Cross-sectional PD, n = 29, mean age 66.2, mean PD duration 9.9 
years, mean H&Y 2.6 
PDD, n = 11, mean age 76.4, mean PD duration 10.5 
years, mean H&Y 3.4
No correlation between PD, OH, cognitive impairment 
(MMSE, FAB). In PDD, cardiovascular symptoms more 
prominent
Hohler et al. 
(2012) [97]
Cross-sectional PD-OH, n = 17
PD without OH, n = 27
PD-OH patients had lower cognitive FIM score and 
lower MMSE, worse motor, walking and balance 
compared to PD without OH. Results not adjusted for 
dopaminergic medication or age
Kim et al. (2012) 
[2]
Cross-sectional PD with normal cognition, n = 25, mean age 63.4, 
mean PD duration 1.8 years, mean H&Y 1.4
PD-MCI, n = 48, mean age 70, mean PD duration 1.9, 
mean H&Y 1,7 
PDD, n = 14, mean age 66.2, mean PD duration 1.6 
years, H&Y 2.1
Drug-naive patients, early stage disease. OH was cor-
related with verbal immediate and delayed memory 
and CHIPS scale. Patients with coexisting OH and SH 
had more severe cognitive impairment and higher 
CHIPS scores. Mean CHIPS score was higher in PDD 
than in others
Pilleri et al. (2013) 
[73]
Cross-sectional PD-OH, n = 23, mean age 64.96, mean PD duration 
11.48 years, mean H&Y 2.76
PD without OH, n = 25, mean age 65.6, mean PD 
duration 11.6 years, mean H&Y 2.76
Among PD-OH patients, impairment of attention, 
visuospatial working memory, verbal delayed recall 
compared to PD without OH were observed. No diffe-
rences in WMH between groups. LEDD were similar
Bae et al. (2014) 
[98]
Cross-sectional PD-OH, n = 18, mean age 61.3, mean PD duration 
13.8 months, mean H&Y 2 
PD without OH, n = 27, mean age 65.5, mean PD 
duration 16.1 months, mean H&Y 2
Drug-naive patients. Verbal memory recognition 
performance worse in PD-OH patients
Anang et al. 
(2014) [99]
Prospective 
– followed up 
mean 4.4 years
PDD, n = 27, mean age 70.5, mean PD duration 6.02 
years, mean H&Y 2,8
PD without dementia, n = 53, mean age 63.5, mean 
PD duration 5.4 years, mean H&Y 2.3
Strong association between OH and risk of dementia. 
SBP drop of >10 mmHg increased odds of developing 
dementia by 84%. Risk factors for developing demen-
tia: baseline MCI, RBD, higher baseline BP, abnormal 
colour vision, proportion of gait involvement, falls and 
freezing. Not adjusted for dopaminergic medication 
or age
Centi et al. (2016) 
[65]
Cross-sectional PD-OH, n = 18, mean age 64.3, mean PD duration 6.7 
years, mean H&Y 2 
PD without OH, n = 19, mean age 65.6, mean PD 
duration 5.7 years, mean H&Y 2 
Controls, n = 18, mean age 62.9
In both PD groups, in supine position deficits in 
sustained attention, response inhibition, semantic 
fluency, verbal memory observed. In upright posture, 
they exacerbated and broadened (phonemic fluency, 
psychomotor speed, auditory working memory) only 
in PD-OH group
Sforza et al. 
(2018) [66]
Cross-sectional PD-OH, n = 14, mean age 73.5, mean PD duration 9 
years, mean H&Y 2.54
PD without OH, n = 14, mean age 72.5, mean PD 
duration 8 years, mean H&Y 2.39
In supine position, no differences in cognition 
between two groups observed. In upright position, 
PD-OH patients were worse at Stroop’s test word 
reading time, interference time, number of errors at 
interference section than patients without OH
Æ
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Study Design Subjects Cognitive outcome 
Cicero et al. 
(2019) [4]
Cross-sectional PD with normal cognition, n = 106, mean age 63.6, 
mean PD duration 4.9 years, mean H&Y 2.2
PD-MCI, n = 79, mean age 66, mean PD duration 6.5 
years, mean H&Y 2.3
OH significantly more frequent in patients with long 
disease duration and associated only with amnestic 
MCI subgroup










PD-OH, n = 69, mean age 71.0, mean PD duration 6.9 
years, mean H&Y 2.4 
PD without OH, n = 157, mean age 64.8, mean PD 
duration 4.5 years, mean H&Y 2.1
Second part:  
PD-OH, n = 28, baseline mean age 62.7, baseline PD 
duration 3.2 years, follow-up interval 5.5 years, base-
line mean H&Y 1.8, follow-up mean H&Y 2.3 
PD without OH, n = 14, baseline mean age 58.3, 
baseline PD duration 2.4 years, follow-up interval 
5.0 years, baseline mean H&Y 1.6, follow-up mean 
H&Y 2.4
PD-OH patients had lower MoCA scores than patients 
without OH. After adjusting for age and disease 
duration, this difference was observed at trend level. 
Furthermore, MoCA score declined more for PD-OH 
group during follow-up period. Cognitive deteriora-
tion did not differ between symptomatic and asymp-
tomatic PD-OH patients, either in cross-sectional or in 
longitudinal analyses
CHIPS scale — cholinergic pathways hyperintensities scale, a measure of WMH; FAB — frontal assessment battery; FIM — functional independence measure; MoCA — Montreal Cognitive Assessment
Table 2 cont. Studies on association between orthostatic hypotension and cognitive decline (modified according to [58], with supplement of later studies)
of the Movement Disorder Society Task Force for Parkinson’s 
Disease with dementia (PDD). The authors found statistically 
significant correlations between non-dipping pattern (nega-
tive) and riser pattern (positive) and dementia [77]. The cor-
relation between abnormal nocturnal BP and dementia was 
independent of age, gender, H&Y score, diabetes, history of 
stroke and WMH [77]. Moreover, non-dipping pattern was 
significantly associated with an increased burden of periven-
tricular hyperintensities [77]. Kim et al. [2] assessed 87 patients 
with early, not treated (medication-naïve) PD at average H&Y 
score of 1.7 ± 0.7 with 24-hour BP recording, 3.0-Tesla MRI 
of the brain and neuropsychological tests. They found MCI 
and PDD in 48 and 14 patients, respectively. The non-dipping 
pattern was present in the majority of patients (79.3%) and 
was associated with higher burden of WMH and lower scores 
in the neuropsychological tests, although the differences were 
not statistically significant [2]. 
As in other neurodegenerative diseases, cognitive deterio-
ration in PD most probably develops as a result of multiple 
underlying processes [79]. In addition to alpha-synuclein 




























Figure 2. Non-dipping pattern at 24h ambulatory blood pressure monitoring in patient with Parkinson’s Disease 
7www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Magdalena Kwaśniak-Butowska et al., Cardiovascular dysautonomia and cognition in PD
Table 3. Medications used to treat orthostatic hypotension in Parkinson’s Disease (modified according to [27])
Medication Recommended dosing Mechanism of action Adverse event
Midodrine 2.5—5 mg three times a day (last dose 
3–4 hours before bedtime)
Direct α1 — adrenergic receptor 
agonist
SH, piloerection, scalp tingling, urinary 
retention; use carefully in congestive heart 
failure and chronic renal failure
Droxidopa* 100–600 mg three times a day (last dose 
3–4 hours before bedtime) or according 
to patient’s needs
Synthetic noradrenaline precursor SH, headache, dizziness, nausea; use care-
fully in congestive heart failure and chronic 
renal failure
Fludrocortisone 0.05–0.2 mg daily Synthetic mineralocorticoid — 
increase of sodium and water 
reabsorption
SH, low potassium level, renal failure, 
myocardial fibrosis, oedema; use carefully in 
congestive heart failure
Pyridostygmine 30–60 mg twice or three times a day Acetyl-cholinesterase inhibitor. 
Marginal efficacy in nOH
Abdominal pain, diarrhoea, sialorrhea, 
excessive sweating, muscle twitches; does 
not cause SH
Atomoxetine 10–18mg twice a day Noradrenaline transporter (NET) 
blocker
SH, insomnia, irritability, decreased appetite
nOH — neurogenic orthostatic hypotension; SH — supine hypertension;  *The only one licensed for this indication
aggregations spread into limbic and neocortical regions, there 
are also accompanying Alzheimer’s type and vascular patholo-
gies [79]. In previous studies, patients with cognitive decline 
due to AD exhibited a non-dipping or a reverse dipping pattern 
significantly more often than healthy controls [80]. Addition-
ally, abnormal nocturnal BP was linked with greater β-amyloid 
deposition in the brain [81]. Abnormal nocturnal BP was 
found to be also associated with cognitive deterioration related 
to cerebrovascular lesions [77, 82]. An absence of dipping 
significantly correlated with vascular cognitive impairment 
and dementia (VCI) and WMH burden [82]. Moreover, there 
was a statistically relevant association between periventricular 
WMH and VCI [82]. The relationship between the extent of 
WMH and abnormal nocturnal BP was also demonstrated 
in PD and it was most pronounced in the reverse dipping 
pattern [78]. Furthermore, the burden of WMH significantly 
correlated with risk of dementia in PD [21]. 
Thus, disturbances of circadian BP rhythm may contribute 
to cognitive decline in PD through many different and inde-
pendent mechanisms.
Treatment options
Before starting the treatment, 24h ambulatory BP mon-
itoring should be performed. This can provide information 
about the frequency of OH episodes as well as the severity 
and duration of SH or abnormal nocturnal BP. 
The first step in OH treatment should be a revision of con-
comitant medications and non-pharmacological interventions. 
Many PD patients previously treated with antihypertensive 
medications (also those for benign prostate hyperplasia as 
alfa-1 receptor antagonists) present OH when dopaminergic 
therapy (levodopa, dopamine agonists as ropinirole, pram-
ipexole or rotigotine) is started, due to a cumulative effect. 
Therefore, doses should be adjusted, or even some medications 
withdrawn, if possible [83].  When it is safe for the PD patient, 
there should be avoided substances causing intravascular 
volume reduction, vasodilatation and affecting noradrenaline 
release or its activity - mainly antihypertensive and tricyclic 
antidepressants [27]. Antiparkinsonian medications such as 
monoamine oxidase B inhibitors (MAO-B, like selegiline), and 
N-Methyl-D-aspartate receptor antagonist (amantadine) may
also exacerbate OH [84].
Fluid and salt intake are recommended, to 2–2.5 L/day and 
by adding 1–2 teaspoons of salt daily respectively [27, 36]. Fast 
but short-lasting increase of BP can be achieved by quickly 
drinking 500 mL of water [85]. Consumption of caffeine and 
alcohol needs to be restricted, due to their diuretic effect [27]. 
Postprandial hypotension can be improved by eating more, but 
smaller, meals, with a limited amount of carbohydrates [86]. 
Other recommended methods are: physical counterpressure 
manoeuvres, abdominal binders, and high waist compression 
stockings [87]. Physical exercises in a lying or sitting position 
may also be helpful [27]. Some patients, despite properly per-
formed non-pharmacological methods, require pharmacologi-
cal treatment to relieve OH symptoms. If OH is symptomatic 
and results in syncope with falls, the use of specific medications 
is recommended: acting via increasing intravascular volume 
(fludrocortisone) or increasing peripheral vascular resistance 
(midodrine, droxidopa, noradrenaline transporter inhibitors). 
Droxidopa is the only licensed medication for OH treatment; 
others are included in experts’ recommendations (Tab. 3). Most 
of them (particularly fludrocortisone and midodrine) cause 
SH as a side effect. Therefore, 24h BP monitoring is crucial to 
avoid long-acting medication effects and in cases of nocturnal 
non-dipping. After midodrine, supine position is not recom-
mended [88]. Short-acting drugs taken before bedtime, such 
as captopril, clonidine, hydralazine, losartan or a nitroglycerin 
patch are recommended in non-dippers [36, 88]. α-blockers, 
β-blockers and short-acting calcium channel blockers should 
be used with caution. 
Moreover, patients should be aware of drugs used for 
different indications which can raise BP (e.g. ibuprofen, 
indomethacin, atomoxetine) [88]. Sleeping with a head-up 
tilt can be helpful for both OH and SH. This reduces night 
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time natriuresis and thus improves morning orthostatic 
tolerance [89]. Patients suffering from SH should also 
avoid lying down during the day and limit water intake 
near bedtime [88]. 
Conclusions
Our literature review suggests a possible association 
between cardiovascular dysautonomia, OH in particular, 
and cognitive impairment not only among PD patients, but 
also in the general population [90–94]. The observed differ-
ences between the studies may result from small groups of 
patients, short follow-ups, no controls, or different methods 
used to assess OH. Cognitive screening tests such as MMSE 
or MoCA are inappropriate for a full assessment of cognition 
in α-synucleinopathies [95]. Active screening for OH, SH and 
abnormal nocturnal BP profile should be provided among PD 
patients, since these treatable abnormalities are commonly 
unrecognised and undertreated [49]. 
A few questions still need to be answered, such as the safe 
level of SH among patients treated for OH, or the way of treat-
ing OH with pre-existing hypertension [70]. The relationship 
between dysautonomia and the possible prevention of cogni-
tive decline needs more thorough studies. 
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